With myocardial infarction (MI), cardiac troponin is released from the heart into circulation, where it can be detected with immunoassays independently quantifying cardiac troponin I (cTnI) or cTnT. There is, however, no single immunoassay that sequentially probes the posttranslational modification status of cTnI or directly characterizes whether circulating cTnI is bound to cTnC and/or cTnT. Here we describe the development of a qualitative immunoassay to directly probe the primary and ternary structure of circulating cTnI through diffractive optics technology (dotLab® System, Axela).
Cardiac-specific troponin can be released into general circulation, where several existing immunoassays can independently quantify either cardiac troponin I (cTnI) 4 or cTnT. Detection of these cardiac-specific proteins in the blood is the current gold standard for the diagnosis of patients with myocardial infarction (MI) (1) (2) (3) (4) . In cardiac muscle, the cTn complex comprises 3 tightly interacting subunits: cTnI, cTnT, and cTnC. Each subunit plays a different functional role in regulating calcium-dependent muscle contractions (1, 5 ) . Under physiological and pathological conditions, cTnT and cTnI in the myocyte can undergo specific posttranslational modifications, including phosphorylation and proteolysis (6 -8 ) . Modification of cTnI can also occur through selective proteolysis at the N-and/or C-terminus with increasing myocardial ischemia (5, 9 -11 ) or pressure overload (12 ) . Some of these posttranslational modifications to the primary cTnI sequence have been detected, albeit in a limited number, in sera, including degradation (13) (14) (15) , phosphorylation (5 ) , and oxidization (15, 16 ) .
There is also a potential for various ternary structures of cTnI in serum: the circulating form of cTnI can be monomeric or form a dimeric or trimeric complex with 1 or both of the other cTn subunits. On the basis of a variety of ELISA assays (which differentiate between cTnI-cTnC and cTnI-cTnT, but not between the dimeric and trimeric complexes), investigators have proposed that the primary circulating form is the cTnI-cTnC complex, at least in a limited number of patients diagnosed with unstable angina (17 ) or MI (18 -20 ) . The first direct measurement of the cTnIcTnC complex was obtained by coupling immunoaffinity capture of circulating cTnI with subsequent trypsin digestion and identification of bound proteins by mass spectrometry (MS) (13 ) . A later study, which measured intact mass by SELDI-TOF MS (cTnI immunocapture followed by MALDI-TOF MS), suggested that the primary circulating form was cTnI with only minor quantities of the cTnI-cTnC complex and no detectable cTnI-cTnT-cTnC or cTnI-cTnT complexes (15, 21 ) . There was no unambiguous identification of the proteins, however, as the identities were assigned on the basis of aligning the intact protein masses with published ones, but with no proteins identified by MS.
Owing to alterations in the primary and ternary structures, cTnI is potentially a heterogeneous analyte, but there is no consensus on the distribution of forms in MI patients. This determination requires an assay that allows interrogation of cTnI at the primary and ternary levels, and that is appropriate for analysis of large patient groups. This assay would also enable researchers to probe whether potential cTnI heterogeneity could facilitate risk stratification (if the various forms segregate with disease severity and/or patient outcome), with the potential to be adapted for the clinical situations.
To develop an immunoassay meeting the challenges, we chose antibodies on the basis of the following criteria: they are (1) well-characterized commercial antibodies with mapped epitopes and (2) preferably purified monoclonal antibodies, or at least affinity-purified polyclonal antibodies (with peptide immunogen).
Here we describe the development of a novel immunoassay that directly interrogates the primary and ternary structures of the circulating form of cTnI within a single assay. The protocol uses diffractive optics technology, bringing together the techniques of grating-based light diffraction and immobilized capture surfaces to allow sequential analysis of the captured antigen (22, 23 ) . This method can directly measure circulating cTnI to determine if it is phosphorylated or degraded at either the N-or C-terminus. In addition, we adapted the assay to determine whether cTnI is associated with cTnC and/or cTnT in a patient diagnosed with MI. 
Materials and Methods

REAGENTS AND SAMPLES
DIFFRACTION-BASED dot Immunoassay
The assays were performed at room temperature in dotLab Sensors with avidin surface chemistry (Axela) on a dotLab System (Axela) (23 ) . We developed different assays as listed below and repeated each assay at least twice. For details of the immunoassays, reproducibility, limit of detection (LOD), and data analysis, see online Supplemental Materials and Methods.
Principle of dot Immunoassay. A capture antibody is immobilized on a specific pattern of lines on the surface of a prism-shaped dotLab Sensor. The sensor surface forms the base of a 10-L flow cell. A series of discrete diffraction beams are generated when illuminating the underside of each assay spot with a laser. The subsequent capture of the analyte (purified analyte or serum) alone or bound to a detector antibody increases the average height of the surface pattern and causes an increase in the diffraction intensity (DI) signal that is recorded in real time. The DI signal is directly related to the size and quantity of the bound complex (22, 23 ) .
Development of cTnI assay. For all cTnI/cTn ITC (cTn ITC being the cardiac troponin complex containing all 3 subunits of I, T, and C) assays, bt-8I-7 mAb was immobilized on an avidin sensor as the capture antibody. 8I-7 [against cTnI residues 137-148 amino acids (aa)] is a well-characterized anti-cTnI antibody (9 ) with epitope in the stable domain (constant region) allowing detection of various degraded forms of cTnI in serum by Western blot (9, 10, 24 ) . 8I-7 is directed against a region of cTnI not involved in the interaction with cTnT and cTnC (1 ), able to immunocapture cTnI, dimeric (I-T and I-C), and/or the trimeric I-T-C cTn complex from serum (13, 25 ) . Other anti-cTnI antibodies with mapped epitopes were used as detectors (see Table 1 and online Supplemental Fig. 1 for details) .
In the immunoassay, DI was monitored in real time with the sequential binding of bt-8I-7, analyte, and detector antibodies (plus amplification if TMB was used) to the assay spot. The change in DI occurred as each protein was added to the complex bound to the sensor. Before the introduction of a reagent, the sensor was blocked with an optimized blocking buffer (to establish the baseline) consisting of BSA [5 g/L in running buffer (PBS with 0.025% Tween-20)] for antibodies, BSA-milk [1% (wt/vol) nonfat milk, 4.5 g/L BSA in running buffer] for purified analyte, or serumblocking buffer [10% (vol/vol) negative control serum in BSA] for all serum samples. We used the ⌬ (change of DI signals from the introduction of a reagent to its removal) to calculate the extent of binding with each step. All binding events were independent from each other, and each was evaluated separately. For data comparison among different experiments, we normalized DI signals of the compared binding step against the ⌬ of bt-8I-7 binding (as "normalized DI"), thus minimizing intersensor variation (such ratio comparison is typical and has been reported previously (23 ) ).
Sequential assay. The sensor was sequentially incubated with a blocking buffer (BSA), capture antibody (bt-8I-7), the second block (BSA-milk), analyte (cTn ITC or rcTnI spiked serum Analyte/sample NA Negative control serum spiked with rcTnI a P3 and HRP-gt-anti-rb were affinity-purified goat polyclonal antibodies; all other antibodies were mouse monoclonal antibodies. See online Supplemental Fig. 1 for epitope map of all anti-cTnI antibodies. Antibodies were diluted according to stock concentrations provided by the manufacturers. b 8I-7 and 3E3 were from Spectral Diagnostics Inc. c P4-14G5 and 1A11 were from Biodesign International. d P3 was from BiosPacific. e MF4 and 7B9 were from Hytest Ltd. f 5E6 and 22B11 from Fitzgerald Industries International. g Although its epitope was unmapped, 7B9 was chosen as the anti-cTnC detector empirically because very few anti-cTnC antibodies are commercially available. h HRP-gt-anti-rb [HRP-conjugated affinity-purified goat-anti-rabbit IgG(HϩL) (minimum cross-reaction to human, mouse, and rat serum proteins)] was from Jackson ImmunoResearch Laboratories. i cTn ITC was purified from human cardiac muscle tissue from individuals diagnosed with heart failure and obtained from Hytest Ltd. Total content of cTn ITC was given per cTnI content, and the concentration was determined by gel-scanning (Enhanced Laser Densitometer) according to the manufacturer. j Purity was tested by 1-dimensional electrophoresis silver stain and Western blot. k NA, not applicable. l cTnI was purified from human cardiac muscle tissue from individuals diagnosed with heart failure and obtained from Hytest Ltd. cTnI concentration was determined spectrophotometrically with A (0.1%, 280 nm, 1 cm) equal to 0.42. This coefficient was calculated from the amino composition of human cTnI according to the manufacturer. m rcTnI and rcTnI were purified as described (26, 27 ) , and their concentrations were determined by BCA assay. n MI patients were from Johns Hopkins University, Division of Cardiology, after institutional review board approval. o Negative control serum was from pooled healthy individuals from Scantibodies Laboratory Inc.
cTnI), the third block (BSA), and the detector antibody, with buffer washes between steps except between a block and its subsequent reagent. Another detector can be introduced after the sensor has been washed and blocked. This cycle of addition of detectors can be repeated many times to build an assay that allows the sequential addition of many different detector antibodies.
TMB-amplified assay. We further modified the assay by using TMB to amplify the DI signal. The HRP-detector antibody was premixed with the 10% (vol/vol) serum sample (diluted in BSA) offline [this premix approach has been reported previously (23 )]. For convenience, we chose overnight incubation at 4°C for all the experiments. We configured the assay so that the sensor was sequentially incubated with BSA, bt-8I-7, serumblocking buffer, premix, and TMB.
Reproducibility. In the sequential assay, cTn ITC captured by bt-8I-7 was sequentially probed with anticTnI MF4 and anti-cTnT 1A11, and the normalized DI values of MF4 or 1A11 were compared. In the TMBamplified assay, bt-8I-7 captured cTnI from a premix of anti-cTnI HRP-3E3 and a cTn ITC -spiked human serum, and the normalized TMB signals were compared.
WESTERN BLOT
cTn ITC , rcTnI , or rcTnI was separated by SDS-PAGE, transferred, and probed following standard protocols (11 ) . See online Supplemental Methods and Materials for details.
Results
DEVELOPMENT OF A NOVEL dot Immunoassay FOR DETECTING cTnI
We developed the dot Immunoassay with bt-8I-7 mAb as a capture antibody, which was initially immobilized on the sensor before introduction of the analyte (purified cTn ITC complex in buffer) and detection with anticTnI 3E3 mAb (epitope 55-94 aa) (Fig. 1A ). Under these conditions, the lowest concentration of cTn ITC detected on the basis of cTnI content was 100 g/L (see online Supplemental Fig. 2 ). The negative control (BSA-milk as analyte) showed no change in DI (Fig.  1B) . The specificity of 8I-7 and 3E3 for cTnI (and all other antibodies) was confirmed by Western blot against purified cTn ITC (Fig. 1F ).
INTEGRITY OF cTnI PRIMARY STRUCTURE AND PHOSPHORYLATION STATUS
To investigate the integrity of cTnI, anti-cTnI mAbs against the N-terminus (P4-14G5 mAb, epitope 1-23 aa) (Fig. 1C) , and P3) and C-terminus (MF4) also detected the lower molecular weight degraded form (Fig. 1F) . We further modified this assay to assess the phosphorylation status of cTnI specifically at amino acid residues (Ser 22 and 23) that are known to be targeted by protein kinase A (8 ) . Here cTn ITC in buffer was captured by bt-8I-7 followed by sequential introduction of the detector antibodies 5E6 mAb (which recognizes cTnI only when residues 22 and 23 are phosphorylated) and 22B11 (which recognizes only the unphosphorylated cTnI) (Fig. 1E) . Western blot analysis against cTn ITC showed that 5E6 detected both the intact and degraded form of cTnI, whereas 22B11 detected only the intact band (Fig. 1F) .
DETECTION OF cTnI-cTnC-cTnT COMPLEX IN A SINGLE EXPERIMENT
To investigate the ternary structure of circulating cTnI, we modified the assay to enable detection of each of the 3 cTn subunits. bt-8I-7 was used as the capture antibody; but different detector antibodies were used to sequentially probe for the other cTn components: specifically, the anti-cTnI antibody MF4, anti-cTnC antibody 7B9, and anti-cTnT antibody 1A11 ( Fig. 2A and analyte-negative control Fig. 2B ). The trimeric complex was detected easily when permuting detector antibody order (data not shown). When cTnI alone (Fig.  2C ) or cTn ITC complex ( Fig. 2A) was used as the analyte (both in buffer), although MF4 could detect both forms of cTnI, the ⌬ (DI), as expected, was smaller for cTnI than cTn ITC , because DI signals correlate to the size of molecules captured on the surface. Only when cTn ITC , not cTnI, was used as the analyte did the 7B9 (anti-cTnC) and 1A11 (anti-cTnT) subsequently detect a signal (Fig. 2, A and C) .
DIRECT DETECTION OF cTnI-cTnC AND cTnI-cTnT COMPLEXES FROM MI PATIENTS
The next step was to adapt the assay's sensitivity to detect circulating cTnI (which is present in ng/L to g/L amounts in MI serum samples (2 ) ). The amplified assay consisted of the sequential addition of bt-8I-7, a premix containing HRP-conjugated detector and serum sample, and TMB (a precipitating substrate for HRP). We preincubated the mixture off-line and found no difference in the amount of cTnI detected if the preincubation was overnight at 4°C or 2 h at room temperature (see online Supplemental Fig. 3 ). Fig. 3A shows the DI tracing of bt-8I-7 capturing the circulating forms of "cTn" (which could be any combinations of cTnI alone or with cTnT and/or cTnC) from an MI patient serum (MI serum #1) when the serum had been preincubated with HRP-7B9 (anti-cTnC). Increased DI signals by TMB amplified the detection of cTnC, Continued on page 1312
Modified cTnI Assay indicating that at least the cTnI-cTnC complex was present in this MI serum. The TMB portions of the DI signals (for detecting cTnC) using the MI serum #1 and a negative control serum (from pooled healthy individuals) as analytes were normalized against the ⌬ values of bt-8I-7 in each run and overlaid in Fig. 3B (see Fig.  3A and online Supplemental Fig. 4 for the full traces of all the data presented in Fig. 3B-D) . HRP-1A11 (anticTnT) also detected the cTnI-cTnT complex in the same sample (Fig. 3C) . HRP-3E3 (anti-cTnI) confirmed the presence of cTnI (Fig. 3D) . cTnC, cTnT, and cTnI were not detected when the negative control serum was used as analyte ( Fig. 3B-D) . We confirmed the presence of cTnI (by HRP-3E3) in serum from 3 additional MI samples. All 4 MI samples had cTnI values determined by another immunoassay, Multi-Array assay (Fig. 3E) . One example (MI serum #2) is shown in online Supplemental Fig. 5 . A nonspecific HRPconjugated goat-anti-rabbit (HRP-gt-anti-rb) antibody was used as a detector antibody-negative control (see online Supplemental Fig. 6A-C) . When both HRP-1A11 and HRP-7B9 were included as the detectors, the combined detection of dimeric and/or trimeric cTn complexes was higher than that of cTnI-cTnC or cTnI-cTnT alone (see online Supplemental Fig. 6 , A and D-F).
We also assessed the integrity of the circulating cTnI in serum from these individuals with MI by using the anti-cTnI antibodies HRP-P4-14G5 (epitope 1-23 aa) and HRP-MF4 (epitope 190 -196 aa) in an MI sample (see online Supplemental Fig. 7) . The assay specificity was confirmed by testing whether HRP-MF4 could differentiate the full-length (rcTnI ) from the C-terminus-truncated (rcTnI ) form. Recombinant rcTnI and rcTnI were used (26, 27 ) . HRP-MF4 detected rcTnI but not rcTnI , which lacks the epitope of MF4, and the results were confirmed by Western blot (see online Supplemental  Fig. 8 ).
REPRODUCIBILITY AND LOD
The unamplified sequential assay based on 1 mg/L cTn ITC had CVs between 10% and 15% for detecting cTnI and cTnT. We calculated the data based on 5 replicates carried out on different days (Fig. 4A-D) . The TMB-amplified assay had a CV of 16.9% for detecting cTnI from a cTn ITC -spiked serum (5 g/ L), with 6 replicates carried out on different days (Fig. 4E-G) . The negative control serum (cTnI ϭ 0) showed minimal DI (mean Ϫ0.002) from 3 replicates (Fig. 5, A, B, and D) . LOD, the lowest concen- (A), DI tracing showing bt-8I-7 mAb capture of the cTn ITC complex (1 mg/L diluted in BSA-milk blocking buffer), followed by sequential detection of cTnI, cTnC, and cTnT with respective antibodies (anti-cTnI MF4 mAb, anti-cTnC 7B9 mAb, and anti-cTnT 1A11 mAb) in a single experiment. B1, BSA blocking buffer; B2, BSA-milk blocking buffer. All nonlabeled portions are running buffer wash. (B), Analyte-negative control of (A). BSA-milk blocking buffer (B2) (blank) instead of cTn ITC was used in an experiment otherwise identical to (A). (C), cTnI analyte control of (A). cTnI (1 mg/L diluted in BSA-milk blocking buffer) instead of cTn ITC was used in an experiment otherwise identical to (A). 
cTnI-cTnC Captured by anti-cTnI (8I-7)
Detected by anti-cTnC (7B9)
cTnI-cTnT Captured by anti-cTnI (8I-7)
Detected by anti-cTnT (1A11)
cTnI confirmation Captured by anti-cTnI (8I-7)
Detected by anti-cTnI (3E3)
B.
C.
D. E. cTnI measurements of MI patients
MultiArray values between the LOD and the control were 0.05 in both assays (Fig. 5D ).
Discussion
We developed a novel sequential immunoassay capable of probing the primary structure of cTnI (N-and C-terminal degradation and phosphorylation at Ser-22 and Ser-23) or its ternary association with cTnT and/or cTnC. Furthermore, we optimized the method and directly determined circulating cTnI bound to cTnC and cTnT in an MI patient, indicating that the dimer or intact cTn (cTnI-cTnT-cTnC) was present. In these complexes, cTnI at least retained sequences from 55-148 aa, which was recognized by both 8I-7 (epitope 137-148 aa, as capture) and 3E3 (epitope 55-94 aa, as detector). This is a qualitative assay, and we have focused on specificity of the assay development. The unamplified dot Immunoassay can be used to sequentially interrogate up to 5 epitopes (1 capture and 4 detector antibodies) of a single protein or components of an antigenantibody complex, all in a single experiment. The uniqueness of this assay is the ability to sequentially apply multiple detector antibodies without antibody stripping, so multiple antibodies can be used to probe the captured antigen in 1 extended assay. The amplified assay enabled detection of various forms of cTnI from MI patients with cTnI concentrations Ն2 g/L (with 1 detector being used per run), although multiple assays have to be performed to determine how cTnI interacts with cTnT and cTnC.
There are several additional properties of this immunoassay. First, it uses real-time detection, which enables independent evaluation of each binding event and acquisition of multiple binding information, in contrast to end-point ELISA that is a single result as the sum of all binding steps. This also facilitated stepwise optimization and troubleshooting and resulted in a shorter running time than that of ELISA assays (17) (18) (19) . Second, the assay is antibody dependent. By selecting well-characterized antibodies with known nonoverlapping epitopes [except anti-cTnC 7B9 (unknown epitope), as few anti-cTnC antibodies are commercially available], it allowed for assessment of primary and ternary structure of cTnI in a single assay. 8I-7 as the capture antibody recognizing epitope in the constant region allowed us to elucidate the degraded forms of cTnI, although it is possible that there are uncharacterized circulating forms of cTnI not captured by 8I-7. Third, amplifying detection of the analyte, by use of an HRP-linked detector antibody and a precipitating form of TMB substrate (22 ) , is a unique feature of the dotLab System that expands the dynamic range of the assay and increases the sensitivity of the real-time assay to the ng/L-g/L (23 ) range; it was previously limited to traditional end-point ELISA (28, 29 ) . Use of precipitable TMB is possible because the instrument allows flow rate to be modified, even to 0, on the basis of experimental needs, and the internal size of the flow tubing is wide enough for the precipitates to pass through. Although mixing was used for washing/incubation steps, the flow was stopped upon introducing TMB. This allowed the intended buildup of local precipitates on the sensor without any concerns about them being washed away and blocking the flow tubing. On instruments such as Biacore Systems (GE Healthcare), where real-time protein-protein interaction data have been obtainable (30 -37 ) , it is impossible to use TMB precipitates to amplify detection because the flow cannot be stopped and the precipitates can block the small channels in the integrated fluidics cartridge where molecules are immobilized. The amplified dot Immunoassay could minimally detect 2 g/L (approximately 84 pmol/L) of cTnI (on the basis of detection of 55-94 aa by 3E3 mAb). N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been minimally detected by dot Immunoassay at 31.25 ng/L (approximately 4 pmol/L) (23 ) .
When probing cTn ITC with anti-cTnI, only 2 antibodies against the N-terminus (P4-14G5 and 22B11) detected the intact cTnI, whereas all other antibodies detected the intact and the N-terminus-degraded cTnI. Although the C-terminus of cTnI is proposed to be degraded first in myocardium from patients undergoing coronary bypass surgery (10 ) and in isolated rat hearts undergoing ischemia (9, 24 ) , and has been detected in the blood of MI patients (11, 14 ) , the N-terminal degradation product has also been observed (11, 13, 38 ) . The purified cTn ITC used in this assay was obtained from heart tissue from individuals diagnosed with heart failure, suggesting a possible difference in the intrinsic pathological degradations between tissue from patients with different heart diseases (ischemia vs heart failure) and those present in serum before or during the purification process. This N-terminal degradation was also phosphorylation dependent (5E6 detected both bands whereas 22B11 detected only the upper band), consistent with previous findings (9, 14 ) . Ultimately, it is only through analysis of larger numbers of individual samples that this seeming ambiguity in terminal degradation will be sorted out.
We have applied the amplified dot Immunoassay to MI patients and have detected cTnI from 4 individuals, and the ternary structure was determined for 1 patient. The assay works for MI patients with cTnI concentrations at 2 g/L or above, but is not sensitive enough to detect cTnI levels in patients with lower concentrations, such as heart failure.
Our current assay is suitable only for research and is not quantitative. For this assay to become quantita-tive, we need to (1) establish standard curves for each form of circulating cTnI, as the raw DI signals cannot be directly used to compare quantity; and (2) harmonize and normalize the multiple dot Immunoassays with each other and with the established clinical assays. The dot Immunoassay has limited throughput and sensitivity. The current platform is not a high-throughput system, although it allows unattended serial analysis of multiple samples. The unamplified sequential assay (multiple detectors in 1 extended assay) worked on high concentrations of cTnI (Ͼ100 g/L), whereas the amplified assay (using HRP-detector/TMB) will be useful in defining the circulating form of cTnI in patients with concentrations Ն2 g/L. This is the first assay that can probe various forms of cTnI in real time, providing researchers with a novel approach to investigate cTnI heterogeneity and facilitate risk stratification.
